ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers

Clinical Microbiology and Infection

Volumn 25, Issue 7, 2019, Pages 807-817

  Tacconelli, E ^a,b   Mazzaferri, F ^b   de Smet, A M ^c   Bragantini, D ^b   Eggimann, P ^d   Huttner, B D ^e,f   Kuijper, E J ^g   Lucet, J C ^h,i   Mutters, N T ^j,k   Sanguinetti, M ^l   Schwaber, M J ^m,n   Souli, M ^o,p   Torre Cisneros, J ^q   Price, J R ^r   Rodriguez Bano J ^s  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF GENEVA   (Switzerland)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h BICHAT HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS DIDEROT   (France)

^j European Committee on Infection Control (EUCIC)   (Switzerland)

^k UNIVERSITY OF FREIBURG   (Germany)

^l FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^m MINISTRY OF HEALTH   (Israel)

ⁿ TEL AVIV UNIVERSITY   (Israel)

^o DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^p UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^q HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^r UNIVERSITY OF SUSSEX   (United Kingdom)

^s HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

more..

Author keywords

Acinetobacter; Carbapenemase; Decolonization; Enterobacteriaceae; Extended spectrum lactamase; Guideline; Multidrug resistant Gram negative; Pseudomonas; Stenotrophomonas

Indexed keywords

ALL CAUSE MORTALITY; AMINOGLYCOSIDE RESISTANT ENTEROBACTERIACEAE; BACTERIAL COLONIZATION; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEPHALOSPORIN RESISTANT ENTEROBACTERIACEAE; COLISTIN RESISTANT GRAM NEGATIVE ORGANISM; COTRIMOXAZOLE RESISTANT STENOTROPHOMONAS MALTOPHILIA; ENTEROBACTERIACEAE; EXTREMELY DRUG RESISTANT PSEUDOMONAS AERUGINOSA; FECAL MICROBIOTA TRANSPLANTATION; FLUOROQUINOLONE RESISTANT ENTEROBACTERIACEAE; GRADE APPROACH; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MULTIDRUG RESISTANT ENTEROBACTERIACEAE; NONHUMAN; PAN DRUG RESISTANT GRAM NEGATIVE ORGANISM; PRIORITY JOURNAL; SHORT SURVEY; ACINETOBACTER BAUMANNII; CROSS INFECTION; DRUG EFFECT; EUROPE; GRAM NEGATIVE INFECTION; IMMUNOCOMPROMISED PATIENT; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 85062076432     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2019.01.005     Document Type: Short Survey

References (81)

1. Tacconelli, E., Carrara, E., Savoldi, A., et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18 (2018), 318–327.
2. European Centre for Disease Prevention and Control. ECDC surveillance report. Annual epidemiological report: antimicrobial resistance and healthcare-associated infections., 2014 Available at: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-annual-epidemiological-report.pdf Published April 2015. (Accessed 30 July 2018)
3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013 Available at: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf Published 23 April 2013. (Accessed 30 July 2018)
4. Tacconelli, E., Cataldo, M.A., Dancer, S.J., et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20 (2014), 1–55.
5. World Health Organization, Practical guidelines for environmental infection control in health care facilities. 2004, World Health Organization, Manila/New Delhi Available at: http://apps.who.int/iris/bitstream/handle/10665/206946/9290222387_eng.pdf?sequence=1&isAllowed=y. (Accessed 15 October 2018)
6. Safdar, N., Bradley, E.A., The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med 121 (2008), 310–315.
7. Vehreschild, M.J., Hamprecht, A., Peterson, L., et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 69 (2014), 3387–3392.
8. Bert, F., Larroque, B., Paugam-Burtz, C., et al. Pretransplant fecal carriage of extended-spectrum β-lactamase–producing Enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis 18 (2012), 908–916.
9. Reddy, P., Malczynski, M., Obias, A., et al. Screening for extended-spectrum β-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 45 (2007), 846–852.
10. Tischendorf, J., de Avila, R.A., Safdar, N., Risk of infection following colonization with carbapenem-resistant Enterobactericeae: a systematic review. Am J Infect Control 44 (2016), 539–543.
11. Dubinsky-Pertzov, B., Temkin, E., Harbarth, Stephan, et al. Carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study. Clin Infect Dis, 2018, 10.1093/cid/ciy768 [Epub ahead of print].
12. Debby, B.D., Ganor, O., Yasmin, M., et al. Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit. Eur J Clin Microbiol Infect Dis 31 (2012), 1811–1817.
13. Papadimitriou-Olivgeris, M., Marangos, M., Fligou, F., et al. KPC-producing Klebsiella pneumoniae enteric colonization acquired during intensive care unit stay: the significance of risk factors for its development and its impact on mortality. Diagn Microbiol Infect Dis 77 (2013), 169–173.
14. Frencken, J.F., Wittekamp, B.H.J., Plantinga, N.L., et al. Associations between enteral colonization with Gram-negative bacteria and intensive care unit-acquired infections and colonization of the tespiratory tract. Clin Infect Dis 66 (2018), 497–503.
15. Gorrie, C.L., Mirceta, M., Wick, R.R., et al. Gastrointestinal carriage Is a major reservoir of Klebsiella pneumoniae infection in intensive care patients. Clin Infect Dis 65 (2017), 208–215.
16. Barbier, F., Pommier, C., Essaied, W., et al. Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?. J Antimicrob Chemother 71 (2016), 1088–1097.
17. Dyakova, E., Bisnauthsing, K.N., Querol-Rubiera, A., Efficacy and acceptability of rectal and perineal sampling for identifying gastrointestinal colonization with extended spectrum β-lactamase Enterobacteriaceae. Clin Microbiol Infect, 23, 2017, 577 e1–577.e3.
18. Bhargava, A., Hayakawa, K., Silverman, E., et al. Risk factors for colonization due to carbapenem-resistant Enterobacteriaceae among patients exposed to long-term acute care and acute care facilities. Infect Control Hosp Epidemiol 35 (2014), 398–405.
19. Swaminathan, M., Sharma, S., Poliansky Blash, S., et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 34 (2013), 809–817.
20. Bart, Y., Paul, M., Eluk, O., et al. Risk factors for recurrence of carbapenem-resistant Enterobacteriaceae carriage: case–control study. Infect Control Hosp Epidemiol 36 (2015), 936–941.
21. Zimmerman, F.S., Assous, M.V., Bdolah-Abram, T., et al. Duration of carriage of carbapenem-resistant Enterobacteriaceae following hospital discharge. Am J Infect Control 41 (2013), 190–194.
22. Bar-Yoseph, H., Hussein, K., Braun, E., Paul, M., Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage: systematic review and meta-analysis. J Antimicrob Chemother 71 (2016), 2729–2739.
23. Vincent, J.L., Jacobs, F., Effect of selective decontamination on antibiotic resistance. Lancet Infect Dis 11 (2011), 337–338.
24. Oostdijk, E.A., Smits, L., de Smet, A.M., et al. Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med 39 (2013), 653–660.
25. Halaby, T., Al Naiemi, N., Kluytmans, J., et al. Reply to ‘colistin resistance during selective digestive tract decontamination is uncommon’. Antimicrob Agents Chemother, 58, 2014, 627.
26. Daneman, N., Sarwar, S., Fowler, R.A., Cuthbertson, B.H., Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 13 (2013), 328–341.
27. de Jonge, E., Schultz, M.J., Spanjaard, L., et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 362 (2003), 1011–1016.
28. de Smet, A.M., Kluytmans, J.A., Cooper, B.S., et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360 (2009), 20–31.
29. de Smet, A.M., Kluytmans, J.A., Blok, H.E., et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 11 (2011), 372–380.
30. Melsen, W.G., de Smet, A.M., Kluytmans, J.A., Bonten, M.J., Selective decontamination of the oral and digestive tract in surgical versus non-surgical patients in intensive care in a cluster-randomized trial. Br J Surg 99 (2012), 232–237.
31. Oostdijk, E.A., Kesecioglu, J., Schultz, M.J., et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA 312 (2014), 1429–1437.
32. Sánchez-Ramírez, C., Hípola-Escalada, S., Cabrera-Santana, M., et al. Long-term use of selective digestive decontamination in an ICU highly endemic for bacterial resistance. Crit Care, 30, 2018, 141.
33. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
34. Magiorakos, A.P., Srinivasan, A., Carey, R.B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
35. Cochrane Effective Practice and Organisation of Care (EPOC). What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC resources for review authors. 2017 Available at: epoc.cochrane.org/epoc-resources-review-authors.
36. Wells, G., Shea, B., O'Connell, D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: ohri.ca/programs/clinical_epidemiology/oxford.asp, 2013.
37. Kavanagh, B.P., The GRADE system for rating clinical guidelines. PLoS Med, 69, 2009, e1000094.
38. Huttner, B., Haustein, T., Uckay, I., et al. Decolonization of intestinal carriage of extended-spectrum B-lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 68 (2013), 2375–2382.
39. Jonsson, A.K., Larsson, A., Tangden, T., et al. A trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum β-lactamases. Infect Ecol Epidemiol, 5, 2015, 28224.
40. Buehlmann, M., Bruderer, T., Frei, R., Widmer, A.F., Effectiveness of a new decolonisation regimen for eradication of extended-spectrum β-lactamase-producing Enterobacteriaceae. J Hosp Infect 77 (2011), 113–117.
41. Decré, D., Gachot, B., Lucet, J.C., et al. Clinical and bacteriologic epidemiology of extended-spectrum β-lactamase-producing strains of Klebsiella pneumoniae in a medical intensive care unit. Clin Infect Dis 27 (1998), 834–844.
42. Oostdijk, E.A.N., de Smet, A., Kesecioglu, J., et al. Decontamination of cephalosporin-resistant Enterobacteriaceae during selective digestive tract decontamination in intensive care units. J Antimicrob Chemother 67 (2012), 2250–2253.
43. Gutierrez-Urbon, J.M., Feal-Cortizas, B., Suarez-Lorenzo, J.M., et al. Failure of a 5 day course of selective digestive decontamination solution in rectal decolonization of ESBL-producing Klebsiella pneumoniae in neonates J Antimicrob Chemother 70 (2015), 625–626.
44. Rieg, S., Kupper, M.F., de With, K., et al. Intestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature. BMC Infect Dis, 15, 2015, 475.
45. Abecasis, F., Sarginson, R.E., Kerr, S., et al. Is selective digestive decontamination useful in controlling aerobic gram-negative bacilli producing extended spectrum β-lactamases?. Microb Drug Resist 17 (2011), 17–23.
46. Paterson, D.L., Singh, N., Rihs, J., et al. Control of an outbreak of infection due to extended-spectrum β-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 33 (2001), 126–128.
47. Troché, G., Joly, L.M., Guibert, M., Zazzo, J.F., Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol 26 (2005), 161–165.
48. Arnan, M., Gudiol, C., Calatayud, L., et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. J Clin Microbiol Infect Dis 30 (2011), 355–360.
49. Liss, B.J., Vehreschild, J.J., Cornely, O.A., et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40 (2012), 613–619.
50. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints Web site. Available at: http://www.eucast.org/clinical_breakpoints. Updated 16 May 2018. Accessed 31 July 2018.
51. Saidel-Odes, L., Polachek, H., Peled, N., et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 33 (2012), 14–19.
52. Nouvenne, A., Ticinesi, A., Meschi, T., Carbapenemase-producing Klebsiella pneumoniae in elderly frail patients admitted to medical wards. Ital J Med 9 (2015), 116–119.
53. Oren, I., Sprecher, H., Finkelstein, R., et al. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: a prospective controlled trial. Am J Infect Control 41 (2013), 1167–1172.
54. Lubbert, C., Faucheux, S., Becker-Rux, D., et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents 42 (2013), 565–570.
55. Machuca, I., Gutierrez-Gutierrez, B., Perez Cortes, S., et al. Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 71 (2016), 3242–3249.
56. De Rosa, F.G., Corcione, S., Raviolo, S., et al. Management of carbapenem-resistant K. pneumoniae in allogenic stem cell transplant recipients: the Turin bundle. New Microbiol 40 (2017), 143–145.
57. Zuckerman, T., Benyamini, N., Sprecher, H., et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 46 (2017), 1226–1230.
58. Lambelet, P., Tascini, C., Fortunato, S., et al. Oral gentamicin therapy for Carbapenem-resistant Klebsiella pneumoniae gut colonization in hematologic patients: a single center experience. New Microbiol 40 (2017), 161–164.
59. Tascini, C., Sbrana, F., Flammini, S., et al. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother 58 (2014), 1972–1976.
60. Brink, A.J., Coetzee, J., Corcoran, C., et al. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol 51 (2013), 369–372.
61. Kronman, M.P., Zerr, D.M., Qin, X., et al. Intestinal decontamination of multidrug-resistant Klebsiella pneumoniae after recurrent infections in an immunocompromised host. Diagn Microbiol Infect Dis 80 (2014), 87–89.
62. Pisney, L.M., Barron, M.A., Kassner, E., et al. Carbapenem-resistant Enterobacteriaceae rectal screening during an outbreak of New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae at an acute care hospital. Infect Control Hosp Epidemiol 35 (2014), 434–436.
63. Dickstein, Y., Edelman, R., Dror, T., Hussein, K., Bar-Lavie, Y., Paul, M., Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers. J Hosp Infect 94 (2016), 54–59.
64. Tannock, G.W., Tiong, I.S., Priest, P., et al. Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities. J Med Microbiol 60 (2011), 366–370.
65. Borer, A., Gilad, J., Porat, N., et al. Impact of 4% chlorhexidine whole-body washing on multidrug-resistant Acinetobacter baumannii skin colonisation among patients in a medical intensive care unit. J Hosp Infect 67 (2007), 149–155.
66. Agusti, C., Pujol, M., Argerich, M.J., et al. Short-term effect of the application of selective decontamination of the digestive tract on different body site reservoir ICU patients colonized by multi-resistant Acinetobacter baumannii. J Antimicrob Chemother 49 (2002), 205–208.
67. Chen, Y.M., Fang, W.F., Kao, H.C., et al. Influencing factors of successful eradication of multidrug-resistant Acinetobacter baumannii in the respiratory tract with aerosolized colistin. Biomed J 37 (2014), 314–320.
68. Kuo, S.C., Lee, Y.T., Yang, S.P., et al. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case–control study. Clin Microbiol Infect 18 (2012), 870–876.
69. Gray, A.P., Allard, R., Pare, R., et al. Management of a hospital outbreak of extensively drug-resistant Acinetobacter baumannii using a multimodal intervention including daily chlorhexidine baths. J Hosp Infect 93 (2016), 29–34.
70. Hsieh, T.C., Chen, F.L., Ou, T.Y., et al. Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization J Microbiol Immunol Infect 49 (2016), 523–530.
71. Manges, A.R., Steiner, T.S., Wright, A.J., Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review. Infect Dis (Lond) 48 (2016), 587–592.
72. Bilinski, J., Grzesiowski, P., Sorensen, N., et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis 65 (2017), 364–370.
73. Davido, B., Batista, R., Michelon, H., et al. Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage?. J Hosp Infect 95 (2017), 433–437.
74. Bilinski, J., Grzesiowski, P., Muszynski, J., et al. Fecal microbiota transplantation inhibits multidrug-resistant gut pathogens: preliminary report performed in an immunocompromised host. Arch Immunol Ther Exp (Warsz) 64 (2016), 255–258.
75. Garcia-Fernandez, S., Morosini, M.I., Cobo, M., et al. Gut eradication of VIM-1 producing ST9 Klebsiella oxytoca after fecal microbiota transplantation for diarrhea caused by a Clostridium difficile hypervirulent R027 strain. Diagn Microbiol Infect Dis, 86, 2016, 4701.
76. Ponte, A., Pinho, R., Mota, M., Fecal microbiota transplantation: is there a role in the eradication of carbapenem-resistant Klebsiella pneumoniae intestinal carriage?. Rev Esp Enferm Dig, 109, 2017, 392.
77. Lagier, J.C., Million, M., Fournier, P.E., et al. Faecal microbiota transplantation for stool decolonization of OXA-48 carbapenemase-producing Klebsiella pneumoniae. J Hosp Infect 90 (2015), 173–174.
78. Friedman-Moraco, R.J., Mehta, A.K., Lyon, G.M., Kraft, C.S., Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant 14 (2014), 477–480.
79. Millan, B., Park, H., Hotte, N., et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 62 (2016), 1479–1486.
80. Crum-Cianflone, N.F., Sullivan, E., Ballon-Landa, G., Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol 53 (2015), 1986–1989.
81. Tacconelli, E., Autenrieth, I.B., Peschel, A., Fighting the enemy within. Science 355 (2017), 689–690.